share_log

Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 5.8%

Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 5.8%

串聯糖尿病護理(納斯達克：TNDM)降價5.8
Financial News Live ·  2022/09/19 14:32

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) fell 5.8% during trading on Monday . The stock traded as low as $53.50 and last traded at $53.96. 2,575 shares were traded during trading, a decline of 100% from the average session volume of 850,181 shares. The stock had previously closed at $57.26.

Tandem糖尿病護理公司(納斯達克代碼：TNDM-GET評級)的股價週一在交易中下跌5.8%。該股一度跌至53.50美元，最後報53.96美元。當日成交量為2,575股，較850,181股的平均日成交量下降100%。該股此前收盤價為57.26美元。

Analyst Upgrades and Downgrades

分析師升級和下調評級

TNDM has been the topic of several research analyst reports. StockNews.com lowered shares of Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research note on Friday, September 9th. Robert W. Baird reduced their target price on Tandem Diabetes Care to $76.00 in a research note on Tuesday, August 9th. TheStreet lowered Tandem Diabetes Care from a "c-" rating to a "d+" rating in a research report on Monday, June 13th. Cowen cut their price target on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Finally, Raymond James decreased their price objective on Tandem Diabetes Care from $125.00 to $90.00 and set an "outperform" rating for the company in a report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Tandem Diabetes Care has a consensus rating of "Hold" and an average price target of $103.36.

技術需求管理一直是幾份研究分析師報告的主題。在9月9日星期五的一份研究報告中，股票新聞網站將Tandem糖尿病護理公司的股票評級從“持有”下調為“賣出”。羅伯特·W·貝爾德在8月9日星期二的一份研究報告中將Tandem糖尿病護理的目標價格下調至76.00美元。華爾街在6月13日星期一的一份研究報告中將Tandem糖尿病護理的評級從“c-”下調至“d+”。Cowen在8月4日星期四的一份報告中將Tandem糖尿病護理的目標價格從141.00美元下調至107.00美元。最後，雷蒙德·詹姆斯將Tandem糖尿病護理的價格目標從125.00美元下調至90美元，並在8月4日星期四的一份報告中為該公司設定了“跑贏大盤”的評級。兩名分析師對該股的評級為賣出，兩名分析師給出了持有評級，四名分析師給出了買入評級。根據MarketBeat的數據，Tandem糖尿病護理公司的共識評級為“持有”，平均目標價為103.36美元。

Get
到達
Tandem Diabetes Care
串聯糖尿病護理
alerts:
警報：

Tandem Diabetes Care Stock Down 4.6 %

糖尿病護理類股下跌4.6%

The company has a market cap of $3.51 billion, a P/E ratio of -241.09 and a beta of 0.95. The company has a debt-to-equity ratio of 0.63, a current ratio of 6.00 and a quick ratio of 5.36. The stock has a fifty day moving average price of $55.02 and a two-hundred day moving average price of $76.13.

該公司市值為35.1億美元，市盈率為-241.09，貝塔係數為0.95.該公司的負債權益比為0.63，流動比率為6.00，速動比率為5.36。該股的50日移動均線價格為55.02美元，200日移動均線價格為76.13美元。

Institutional Investors Weigh In On Tandem Diabetes Care

機構投資者對糖尿病護理的看法

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Byrne Asset Management LLC bought a new stake in shares of Tandem Diabetes Care in the 4th quarter worth $34,000. Exane Derivatives bought a new stake in Tandem Diabetes Care in the 1st quarter worth about $33,000. CI Investments Inc. increased its stake in Tandem Diabetes Care by 10,566.7% in the 1st quarter. CI Investments Inc. now owns 320 shares of the medical device company's stock valued at $37,000 after buying an additional 317 shares during the last quarter. Sandy Cove Advisors LLC bought a new position in shares of Tandem Diabetes Care during the 1st quarter worth approximately $46,000. Finally, KRS Capital Management LLC bought a new position in shares of Tandem Diabetes Care during the 4th quarter worth approximately $60,000. 95.28% of the stock is owned by hedge funds and other institutional investors.
一些機構投資者和對衝基金最近買賣了該股的股票。Byrne Asset Management LLC在第四季度購買了Tandem糖尿病護理公司價值3.4萬美元的新股。Exane衍生品在第一季度購買了Tandem糖尿病護理公司的新股份，價值約3.3萬美元。CI投資公司在第一季度將其在Tandem糖尿病護理公司的股份增加了10566.7%。CI Investments Inc.現在持有這家醫療設備公司320股股票，價值3.7萬美元，此前該公司在上個季度又購買了317股。Sandy Cove Advisors LLC在第一季度購買了Tandem糖尿病護理公司的新股票，價值約4.6萬美元。最後，KRS資本管理公司在第四季度購買了Tandem糖尿病護理公司的新股票，價值約6萬美元。95.28%的股票由對衝基金和其他機構投資者持有。

About Tandem Diabetes Care

關於糖尿病患者的護理

(Get Rating)

(獲取評級)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Tandem糖尿病護理公司是一家醫療設備公司，為美國和國際上的胰島素依賴型糖尿病患者設計、開發和銷售各種產品。該公司的旗艦產品是T：SILM X2胰島素輸送系統，這是一個由T：SILM X2泵、300個單位的一次性胰島素盒和輸液器組成的泵平臺。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
  • Still Lovin' It: Investors Keep Visiting McDonald's
  • Did FedEx Just Deliver A Buying Opportunity?
  • Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
  • Upwork Shares Stumble into Bargain Territory
  • Kroger's is Your One-Stop Consumer Staples Stock
  • 免費獲取StockNews.com關於串聯糖尿病護理(TNDM)的研究報告
  • 仍然愛着它：投資者繼續光顧麥當勞
  • 聯邦快遞剛剛提供了一個買入機會嗎？
  • 自動區重新進入拉力賽模式，新高在望
  • Upwork股價跌入便宜貨領域
  • 克羅格百貨是你的一站式消費者史泰博股票

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

接受每日串聯糖尿病護理的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Tandem糖尿病護理和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論